 

Aptar is a resilient company that serves patients and consumers across a variety of end markets, including pharmaceuticals, food and beverages, and beauty and home. The company's commitment to research and development has led to the development of innovative solutions, including active material science technology, unidose powder devices, and nasal sprays. In the first quarter of 2021, Aptar achieved an adjusted EBITDA margin comparable to the prior year, despite a mix shift within its pharmaceuticals segment and a relative mix across its three segments. The company's food and beverages segment delivered a stellar performance, driven by strong demand for innovative food dispensing closures. The beauty and home segment experienced a decline in sales to the beauty market due to continued low levels of retail beauty activity related to the ongoing pandemic. Aptar is cautiously optimistic about the second half of the year and is maintaining initiatives to contain costs and manage inflation. The company's balance sheet remains strong, with a leverage ratio of 1.4 and a capital expenditure range of $300 million to $330 million for the year. Aptar's positive mid